Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 100

1.

Long-term durable efficacy of autologous stem cell transplantation in POEMS syndrome.

Saini NY, Patel RD, Varma A, Bashir Q, Delgado R, Rondon G, Popat U, Hosing C, Nieto Y, Kebriaei P, Weber DM, Thomas SK, Lee HC, Manasanch EE, Orlowski RZ, Champlin RE, Qazilbash MH, Patel KK.

Am J Hematol. 2019 Mar;94(3):E72-E74. doi: 10.1002/ajh.25375. Epub 2018 Dec 21. No abstract available.

PMID:
30548467
2.

Bortezomib, lenalidomide, and dexamethasone with panobinostat for front-line treatment of patients with multiple myeloma who are eligible for transplantation: a phase 1 trial.

Manasanch EE, Shah JJ, Lee HC, Weber DM, Thomas SK, Amini B, Feng L, Berkova Z, Hildebrandt M, Orlowski RZ.

Lancet Haematol. 2018 Dec;5(12):e628-e640. doi: 10.1016/S2352-3026(18)30174-1.

PMID:
30501870
3.

Primary plasma cell leukemia: autologous stem cell transplant in an era of novel induction drugs.

Gowda L, Shah M, Badar I, Bashir Q, Shah N, Patel K, Kanagal-Shamanna R, Mehta R, Weber DM, Lee HC, Manasanch EE, Shah A, Thomas SK, Parmar S, Nieto Y, Orlowski RZ, Champlin R, Qazilbash MH.

Bone Marrow Transplant. 2018 Nov 16. doi: 10.1038/s41409-018-0392-1. [Epub ahead of print]

PMID:
30446740
4.

Melphalan-based autologous transplant in octogenarian multiple myeloma patients.

Saini NY, Patel R, Varma A, Bashir Q, Delgado R, Rondon G, Popat UR, Hosing CM, Nieto Y, Kebriaei P, Alousi AM, Ahmed S, Weber DM, Thomas SK, Lee HC, Manasanch EE, Patel KK, Orlowski RZ, Champlin RE, Qazilbash MH.

Am J Hematol. 2019 Jan;94(1):E2-E5. doi: 10.1002/ajh.25310. Epub 2018 Oct 31. No abstract available.

PMID:
30300461
5.

Carfilzomib-based combination regimens are highly effective frontline therapies for multiple myeloma and Waldenström's macroglobulinemia.

Chaudhry M, Steiner R, Claussen C, Patel K, Lee H, Weber D, Thomas S, Feng C, Amini B, Orlowski R, Feng L, Manasanch EE.

Leuk Lymphoma. 2018 Sep 19:1-7. doi: 10.1080/10428194.2018.1508668. [Epub ahead of print]

PMID:
30227761
6.

High-risk myeloma and minimal residual disease postautologous-HSCT predict worse outcomes.

Hu B, Thall P, Milton DR, Sasaki K, Bashir Q, Shah N, Patel K, Popat U, Hosing C, Nieto Y, Lin P, Delgado R, Jorgensen J, Manasanch E, Weber D, Thomas S, Orlowski RZ, Champlin R, Qazilbash MH.

Leuk Lymphoma. 2018 Jul 22:1-11. doi: 10.1080/10428194.2018.1485908. [Epub ahead of print]

PMID:
30032678
7.

Impact of Induction Therapy on the Outcome of Immunoglobulin Light Chain Amyloidosis after Autologous Hematopoietic Stem Cell Transplantation.

Afrough A, Saliba RM, Hamdi A, Honhar M, Varma A, Cornelison AM, Rondon G, Parmar S, Shah ND, Bashir Q, Hosing C, Popat U, Weber DM, Thomas S, Orlowski RZ, Champlin RE, Qazilbash MH.

Biol Blood Marrow Transplant. 2018 Nov;24(11):2197-2203. doi: 10.1016/j.bbmt.2018.07.010. Epub 2018 Aug 9.

PMID:
30016656
8.

NCCN Guidelines Insights: Multiple Myeloma, Version 3.2018.

Kumar SK, Callander NS, Alsina M, Atanackovic D, Biermann JS, Castillo J, Chandler JC, Costello C, Faiman M, Fung HC, Godby K, Hofmeister C, Holmberg L, Holstein S, Huff CA, Kang Y, Kassim A, Liedtke M, Malek E, Martin T, Neppalli VT, Omel J, Raje N, Singhal S, Somlo G, Stockerl-Goldstein K, Weber D, Yahalom J, Kumar R, Shead DA.

J Natl Compr Canc Netw. 2018 Jan;16(1):11-20. doi: 10.6004/jnccn.2018.0002.

PMID:
29295877
9.

Chondroitin sulfate proteoglycan serglycin influences protein cargo loading and functions of tumor-derived exosomes.

Purushothaman A, Bandari SK, Chandrashekar DS, Jones RJ, Lee HC, Weber DM, Orlowski RZ.

Oncotarget. 2017 Aug 27;8(43):73723-73732. doi: 10.18632/oncotarget.20564. eCollection 2017 Sep 26.

10.

A case control study of syngeneic transplantation versus autologous transplantation for multiple myeloma: two decades of experiences from a single center.

Mohyuddin GR, Faisal MS, Badar T, Shah N, Bashir Q, Patel KK, Hosing C, Popat UR, Rondon G, Delgado R, Shah JJ, Weber DM, Thomas SK, Manasanch EE, Orlowski RZ, Champlin RE, Qazilbash MH.

Leuk Lymphoma. 2018 Feb;59(2):515-518. doi: 10.1080/10428194.2017.1344906. Epub 2017 Jul 3. No abstract available.

PMID:
28673185
11.

Clinical implications of cytogenetic heterogeneity in multiple myeloma patients with TP53 deletion.

Hao S, Lin P, Medeiros LJ, Fang L, Carballo-Zarate AA, Konoplev SN, Sargent RL, Weber DM, Thomas SK, Manasanch EE, Orlowski RZ, Lu X.

Mod Pathol. 2017 Oct;30(10):1378-1386. doi: 10.1038/modpathol.2017.63. Epub 2017 Jun 30.

12.

Phase II study of the c-MET inhibitor tivantinib (ARQ 197) in patients with relapsed or relapsed/refractory multiple myeloma.

Baljevic M, Zaman S, Baladandayuthapani V, Lin YH, de Partovi CM, Berkova Z, Amini B, Thomas SK, Shah JJ, Weber DM, Fu M, Cleeland CS, Wang XS, Stellrecht CM, Davis RE, Gandhi V, Orlowski RZ.

Ann Hematol. 2017 Jun;96(6):977-985. doi: 10.1007/s00277-017-2980-3. Epub 2017 Mar 23.

13.

Additional-structural-chromosomal aberrations are associated with inferior clinical outcome in patients with hyperdiploid multiple myeloma: a single-institution experience.

Carballo-Zarate AA, Medeiros LJ, Fang L, Shah JJ, Weber DM, Thomas SK, Manasanch EE, Hao S, Shen Q, Orlowski RZ, Lin P, Lu X.

Mod Pathol. 2017 Jun;30(6):843-853. doi: 10.1038/modpathol.2017.3. Epub 2017 Mar 10.

14.

Multiple Myeloma, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology.

Kumar SK, Callander NS, Alsina M, Atanackovic D, Biermann JS, Chandler JC, Costello C, Faiman M, Fung HC, Gasparetto C, Godby K, Hofmeister C, Holmberg L, Holstein S, Huff CA, Kassim A, Liedtke M, Martin T, Omel J, Raje N, Reu FJ, Singhal S, Somlo G, Stockerl-Goldstein K, Treon SP, Weber D, Yahalom J, Shead DA, Kumar R.

J Natl Compr Canc Netw. 2017 Feb;15(2):230-269.

PMID:
28188192
15.

Advances and practical use of monoclonal antibodies in multiple myeloma therapy.

Lee HC, Weber DM.

Hematology Am Soc Hematol Educ Program. 2016 Dec 2;2016(1):512-520. Review.

16.

Lenalidomide, Thalidomide, and Pomalidomide Reactivate the Epstein-Barr Virus Lytic Cycle through Phosphoinositide 3-Kinase Signaling and Ikaros Expression.

Jones RJ, Iempridee T, Wang X, Lee HC, Mertz JE, Kenney SC, Lin HC, Baladandayuthapani V, Dawson CW, Shah JJ, Weber DM, Orlowski RZ.

Clin Cancer Res. 2016 Oct 1;22(19):4901-4912. Epub 2016 Jun 13.

17.

Tight Junction Protein 1 Modulates Proteasome Capacity and Proteasome Inhibitor Sensitivity in Multiple Myeloma via EGFR/JAK1/STAT3 Signaling.

Zhang XD, Baladandayuthapani V, Lin H, Mulligan G, Li B, Esseltine DW, Qi L, Xu J, Hunziker W, Barlogie B, Usmani SZ, Zhang Q, Crowley J, Hoering A, Shah JJ, Weber DM, Manasanch EE, Thomas SK, Li BZ, Wang HH, Zhang J, Kuiatse I, Tang JL, Wang H, He J, Yang J, Milan E, Cenci S, Ma WC, Wang ZQ, Davis RE, Yang L, Orlowski RZ.

Cancer Cell. 2016 May 9;29(5):639-652. doi: 10.1016/j.ccell.2016.03.026. Epub 2016 Apr 28.

18.

NCCN Guidelines Insights: Multiple Myeloma, Version 3.2016.

Anderson KC, Alsina M, Atanackovic D, Biermann JS, Chandler JC, Costello C, Djulbegovic B, Fung HC, Gasparetto C, Godby K, Hofmeister C, Holmberg L, Holstein S, Huff CA, Kassim A, Krishnan AY, Kumar SK, Liedtke M, Lunning M, Raje N, Reu FJ, Singhal S, Somlo G, Stockerl-Goldstein K, Treon SP, Weber D, Yahalom J, Shead DA, Kumar R.

J Natl Compr Canc Netw. 2016 Apr;14(4):389-400.

19.

Outcome of patients with systemic light chain amyloidosis with concurrent renal and cardiac involvement.

Badar T, Cornelison AM, Shah ND, Bashir Q, Parmar S, Patel K, Hosing C, Popat U, Weber DM, Thomas SK, Shah JJ, Orlowski RZ, Champlin RE, Qazilbash MH.

Eur J Haematol. 2016 Oct;97(4):342-7. doi: 10.1111/ejh.12736. Epub 2016 Feb 15.

PMID:
26773409
20.

Outcome of Patients With Nonsecretory Multiple Myeloma After Autologous Hematopoietic Stem Cell Transplantation.

Jacobs RW, Saliba RM, Sasaki K, Farhan S, Armas A, Shah ND, Bashir Q, Qureshi S, Rondon G, Hosing C, Popat U, Parmar S, Shah JJ, Wang M, Weber DM, Thomas SK, Orlowski RZ, Champlin RE, Qazilbash MH.

Clin Lymphoma Myeloma Leuk. 2016 Jan;16(1):36-42. doi: 10.1016/j.clml.2015.11.005. Epub 2015 Dec 1.

PMID:
26702475
21.

Multiple Myeloma, Version 2.2016: Clinical Practice Guidelines in Oncology.

Anderson KC, Alsina M, Atanackovic D, Biermann JS, Chandler JC, Costello C, Djulbegovic B, Fung HC, Gasparetto C, Godby K, Hofmeister C, Holmberg L, Holstein S, Huff CA, Kassim A, Krishnan AY, Kumar SK, Liedtke M, Lunning M, Raje N, Singhal S, Smith C, Somlo G, Stockerl-Goldstein K, Treon SP, Weber D, Yahalom J, Shead DA, Kumar R; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2015 Nov;13(11):1398-435.

22.

Clinicopathologic features and outcomes of lymphoplasmacytic lymphoma patients with monoclonal IgG or IgA paraprotein expression.

Cao X, Medeiros LJ, Xia Y, Wang X, Thomas SK, Loghavi S, Li X, Shah JJ, Gustafson SA, Weber DM, Miranda RN, Xu-Monette ZY, Orlowski RZ, Young KH.

Leuk Lymphoma. 2016 May;57(5):1104-13. doi: 10.3109/10428194.2015.1096357. Epub 2015 Dec 23.

PMID:
26421453
23.

Membranous nephropathy in autologous hematopoietic stem cell transplant: autologous graft-versus-host disease or autoimmunity induction?

Abudayyeh A, Truong LD, Beck LH Jr, Weber DM, Rezvani K, Abdelrahim M.

Clin Kidney J. 2015 Aug;8(4):440-4. doi: 10.1093/ckj/sfv036. Epub 2015 Jun 1.

24.

Student Perception of Improvement in Communication and Value in 2 Interprofessional Education Delivery Formats.

Arentsen A, Welsh D, Jones M, Weber D, Taylor S, Kuperstein J, Rayens MK, Salt E.

Nurse Educ. 2016 Mar-Apr;41(2):90-2. doi: 10.1097/NNE.0000000000000201.

PMID:
26237007
25.

Crystal-storing histiocytosis: a clinicopathological study of 13 cases.

Kanagal-Shamanna R, Xu-Monette ZY, Miranda RN, Dogan A, Zou D, Luthra R, Weber DM, O'Malley DP, Jorgensen JL, Khoury JD, Bueso-Ramos CE, Orlowski RZ, Medeiros LJ, Young KH.

Histopathology. 2016 Mar;68(4):482-91. doi: 10.1111/his.12768. Epub 2015 Aug 27.

26.

Waldenström macroglobulinemia with extramedullary involvement at initial diagnosis portends a poorer prognosis.

Cao X, Ye Q, Orlowski RZ, Wang X, Loghavi S, Tu M, Thomas SK, Shan J, Li S, Qazilbash M, Yin CC, Weber D, Miranda RN, Xu-Monette ZY, Medeiros LJ, Young KH.

J Hematol Oncol. 2015 Jun 24;8:74. doi: 10.1186/s13045-015-0172-y.

27.

Targeting the Spleen Tyrosine Kinase with Fostamatinib as a Strategy against Waldenström Macroglobulinemia.

Kuiatse I, Baladandayuthapani V, Lin HY, Thomas SK, Bjorklund CC, Weber DM, Wang M, Shah JJ, Zhang XD, Jones RJ, Ansell SM, Yang G, Treon SP, Orlowski RZ.

Clin Cancer Res. 2015 Jun 1;21(11):2538-45. doi: 10.1158/1078-0432.CCR-14-1462. Epub 2015 Mar 6.

28.

A critical role of autocrine sonic hedgehog signaling in human CD138+ myeloma cell survival and drug resistance.

Liu Z, Xu J, He J, Zheng Y, Li H, Lu Y, Qian J, Lin P, Weber DM, Yang J, Yi Q.

Blood. 2014 Sep 25;124(13):2061-71. doi: 10.1182/blood-2014-03-557298. Epub 2014 Jul 21.

29.

Primary cutaneous plasmacytoma.

Wuu A, Bangert SD, Weber DM, Hymes SR.

Cutis. 2014 Jun;93(6):E19-21. No abstract available.

PMID:
24999652
30.

Electroacupuncture for thalidomide/bortezomib-induced peripheral neuropathy in multiple myeloma: a feasibility study.

Garcia MK, Cohen L, Guo Y, Zhou Y, You B, Chiang J, Orlowski RZ, Weber D, Shah J, Alexanian R, Thomas S, Romaguera J, Zhang L, Badillo M, Chen Y, Wei Q, Lee R, Delasalle K, Green V, Wang M.

J Hematol Oncol. 2014 May 9;7:41. doi: 10.1186/1756-8722-7-41.

31.

The multiple oral presentations of multiple myeloma.

Cardoso RC, Gerngross PJ, Hofstede TM, Weber DM, Chambers MS.

Support Care Cancer. 2014 Jan;22(1):259-67. doi: 10.1007/s00520-013-1960-y. Epub 2013 Sep 20.

32.

IMWG consensus on risk stratification in multiple myeloma.

Chng WJ, Dispenzieri A, Chim CS, Fonseca R, Goldschmidt H, Lentzsch S, Munshi N, Palumbo A, Miguel JS, Sonneveld P, Cavo M, Usmani S, Durie BG, Avet-Loiseau H; International Myeloma Working Group.

Leukemia. 2014 Feb;28(2):269-77. doi: 10.1038/leu.2013.247. Epub 2013 Aug 26. Review.

PMID:
23974982
33.

PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma.

Richardson PG, Schlossman RL, Alsina M, Weber DM, Coutre SE, Gasparetto C, Mukhopadhyay S, Ondovik MS, Khan M, Paley CS, Lonial S.

Blood. 2013 Oct 3;122(14):2331-7. doi: 10.1182/blood-2013-01-481325. Epub 2013 Aug 15.

34.

Mechanistic studies on the synergistic cytotoxicity of the nucleoside analogs gemcitabine and clofarabine in multiple myeloma: relevance of p53 and its clinical implications.

Valdez BC, Wang G, Murray D, Nieto Y, Li Y, Shah J, Turturro F, Wang M, Weber DM, Champlin RE, Qazilbash MH, Andersson BS.

Exp Hematol. 2013 Aug;41(8):719-30. doi: 10.1016/j.exphem.2013.04.009. Epub 2013 May 3.

35.

Multiple myeloma, version 1.2013.

Anderson KC, Alsina M, Bensinger W, Biermann JS, Cohen AD, Devine S, Djulbegovic B, Faber EA Jr, Gasparetto C, Hernandez-Illizaliturri F, Huff CA, Kassim A, Krishnan AY, Liedtke M, Meredith R, Raje N, Schriber J, Singhal S, Somlo G, Stockerl-Goldstein K, Treon SP, Weber D, Yahalom J, Yunus F, Shead DA, Kumar R.

J Natl Compr Canc Netw. 2013 Jan 1;11(1):11-7.

PMID:
23307977
36.

Waldenström's macroglobulinemia/lymphoplasmacytic lymphoma, version 2.2013.

Anderson KC, Alsina M, Bensinger W, Biermann JS, Cohen AD, Devine S, Djulbegovic B, Faber EA Jr, Gasparetto C, Hernandez-Ilizaliturri F, Huff CA, Kassim A, Krishnan AY, Medeiros BC, Meredith R, Raje N, Schriber J, Singhal S, Somlo G, Stockerl-Goldstein K, Treon SP, Tricot G, Weber DM, Yahalom J, Yunus F, Kumar R, Shead DA; NCCN (National Comprehensive Cancer Network).

J Natl Compr Canc Netw. 2012 Oct 1;10(10):1211-9.

PMID:
23054875
37.

Phase I trial of vorinostat combined with bortezomib for the treatment of relapsing and/or refractory multiple myeloma.

Weber DM, Graef T, Hussein M, Sobecks RM, Schiller GJ, Lupinacci L, Hardwick JS, Jagannath S.

Clin Lymphoma Myeloma Leuk. 2012 Oct;12(5):319-24. doi: 10.1016/j.clml.2012.07.007.

PMID:
23040438
38.

Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma.

Kuhn DJ, Berkova Z, Jones RJ, Woessner R, Bjorklund CC, Ma W, Davis RE, Lin P, Wang H, Madden TL, Wei C, Baladandayuthapani V, Wang M, Thomas SK, Shah JJ, Weber DM, Orlowski RZ.

Blood. 2012 Oct 18;120(16):3260-70. doi: 10.1182/blood-2011-10-386789. Epub 2012 Aug 29.

39.

Lenalidomide in combination with dexamethasone improves survival and time-to-progression in patients ≥65 years old with relapsed or refractory multiple myeloma.

Chanan-Khan AA, Lonial S, Weber D, Borrello I, Foà R, Hellmann A, Dimopoulos M, Swern AS, Knight R.

Int J Hematol. 2012 Aug;96(2):254-62. doi: 10.1007/s12185-012-1125-7. Epub 2012 Jul 3.

40.

Curability of multiple myeloma.

Alexanian R, Delasalle K, Wang M, Thomas S, Weber D.

Bone Marrow Res. 2012;2012:916479. doi: 10.1155/2012/916479. Epub 2012 May 23.

41.

Case 181: synovitis acne pustulosis hyperostosis osteitis (SAPHO) syndrome.

Sweeney SA, Kumar VA, Tayar J, Weber DM, Safdar A, Alonso C, Hymes S.

Radiology. 2012 May;263(2):613-7. doi: 10.1148/radiol.12101436. No abstract available.

PMID:
22517965
42.

A review of second primary malignancy in patients with relapsed or refractory multiple myeloma treated with lenalidomide.

Dimopoulos MA, Richardson PG, Brandenburg N, Yu Z, Weber DM, Niesvizky R, Morgan GJ.

Blood. 2012 Mar 22;119(12):2764-7. doi: 10.1182/blood-2011-08-373514. Epub 2012 Feb 9. Review.

43.

Predictors of prolonged survival after allogeneic hematopoietic stem cell transplantation for multiple myeloma.

Bashir Q, Khan H, Orlowski RZ, Amjad AI, Shah N, Parmar S, Wei W, Rondon G, Weber DM, Wang M, Thomas SK, Shah JJ, Qureshi SR, Dinh YT, Popat U, Anderlini P, Hosing C, Giralt S, Champlin RE, Qazilbash MH.

Am J Hematol. 2012 Mar;87(3):272-6. doi: 10.1002/ajh.22273. Epub 2012 Jan 9.

44.

Multiple myeloma.

Anderson KC, Alsina M, Bensinger W, Biermann JS, Chanan-Khan A, Cohen AD, Devine S, Djulbegovic B, Faber EA Jr, Gasparetto C, Huff CA, Kassim A, Medeiros BC, Meredith R, Raje N, Schriber J, Singhal S, Somlo G, Stockerl-Goldstein K, Treon SP, Tricot G, Weber DM, Yahalom J, Yunus F; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2011 Oct;9(10):1146-83. No abstract available. Erratum in: J Natl Compr Canc Netw. 2011 Dec 1;9(12):xxv.

PMID:
21975914
45.

Adjusting for patient crossover in clinical trials using external data: a case study of lenalidomide for advanced multiple myeloma.

Ishak KJ, Caro JJ, Drayson MT, Dimopoulos M, Weber D, Augustson B, Child JA, Knight R, Iqbal G, Dunn J, Shearer A, Morgan G.

Value Health. 2011 Jul-Aug;14(5):672-8. doi: 10.1016/j.jval.2011.02.1182.

46.

Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study.

Kumar SK, Lee JH, Lahuerta JJ, Morgan G, Richardson PG, Crowley J, Haessler J, Feather J, Hoering A, Moreau P, LeLeu X, Hulin C, Klein SK, Sonneveld P, Siegel D, Bladé J, Goldschmidt H, Jagannath S, Miguel JS, Orlowski R, Palumbo A, Sezer O, Rajkumar SV, Durie BG; International Myeloma Working Group.

Leukemia. 2012 Jan;26(1):149-57. doi: 10.1038/leu.2011.196. Epub 2011 Jul 29. Erratum in: Leukemia. 2012 May;26(5):1153. Nari, Hareth [corrected to Nahi, Hareth].

47.

Feasibility of autologous hematopoietic stem cell transplant in patients aged ≥70 years with multiple myeloma.

Bashir Q, Shah N, Parmar S, Wei W, Rondon G, Weber DM, Wang M, Orlowski RZ, Thomas SK, Shah J, Qureshi SR, Dinh YT, Popat U, Anderlini P, Hosing C, Giralt S, Champlin RE, Qazilbash MH.

Leuk Lymphoma. 2012 Jan;53(1):118-22. doi: 10.3109/10428194.2011.606942. Epub 2011 Aug 24.

PMID:
21780997
48.

Solitary plasmacytomas: outcome and prognostic factors after definitive radiation therapy.

Reed V, Shah J, Medeiros LJ, Ha CS, Mazloom A, Weber DM, Arzu IY, Orlowski RZ, Thomas SK, Shihadeh F, Alexanian R, Dabaja BS.

Cancer. 2011 Oct 1;117(19):4468-74. doi: 10.1002/cncr.26031. Epub 2011 Mar 22.

49.

Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3.

Dimopoulos M, Kyle R, Fermand JP, Rajkumar SV, San Miguel J, Chanan-Khan A, Ludwig H, Joshua D, Mehta J, Gertz M, Avet-Loiseau H, Beksaç M, Anderson KC, Moreau P, Singhal S, Goldschmidt H, Boccadoro M, Kumar S, Giralt S, Munshi NC, Jagannath S; International Myeloma Workshop Consensus Panel 3.

Blood. 2011 May 5;117(18):4701-5. doi: 10.1182/blood-2010-10-299529. Epub 2011 Feb 3.

50.

Effects of lenalidomide and dexamethasone treatment duration on survival in patients with relapsed or refractory multiple myeloma treated with lenalidomide and dexamethasone.

San-Miguel JF, Dimopoulos MA, Stadtmauer EA, Rajkumar SV, Siegel D, Bravo ML, Olesnyckyj M, Knight RD, Zeldis JB, Harousseau JL, Weber DM.

Clin Lymphoma Myeloma Leuk. 2011 Feb;11(1):38-43. doi: 10.3816/CLML.2010.n.120.

PMID:
21273172

Supplemental Content

Loading ...
Support Center